Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Higgins · SciRah

Researcher profile · Semantic Scholar

D. Higgins

Share profile

D. Higgins — researcher profile on SciRah

h-index: 13
Works: 58
Citations: 871

Most-cited papers

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
M. L. Disis, D. Wallace, T. Gooley, Y. Dang +11 more
2009Journal of Clinical Oncology300 citations Open access
Semantic Scholar
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial
L. G. Salazar, Hai-Ling Lu, J. Reichow, J. Childs +6 more
2017JAMA Oncology98 citations Open access
Semantic Scholar
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.
M. L. Disis, K. Guthrie, Y. Liu, A. Coveler +4 more
2022JAMA Oncology87 citations Open access
Semantic Scholar
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity
V. Goodell, J. Waisman, L. G. Salazar, Corazon delaRosa +6 more
2008Molecular Cancer Therapeutics60 citations
Semantic Scholar
Elimination of IL-10 inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent anti-tumor activity
D. Cecil, G. Holt, K. Park, E. Gad +4 more
2014Cancer Research45 citations Open access
Semantic Scholar
Tumor Antigen–Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming
Y. Dang, K. Knutson, V. Goodell, Corazon delaRosa +4 more
2006Clinical Cancer Research35 citations
Semantic Scholar
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers
M. Disis, Y. Dang, A. Coveler, Edmond A Marzbani +7 more
2013Cancer Immunology and Immunotherapy34 citations Open access
Semantic Scholar
Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo
S. Stanton, J. Eary, Edmond A Marzbani, D. Mankoff +6 more
2016Journal of Immunotherapy for Cancer24 citations Open access
Semantic Scholar
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
J. Liao, W. Gwin, R. Urban, Katie M. Hitchcock-Bernhardt +13 more
2021Journal for ImmunoTherapy of Cancer23 citations Open access
Semantic Scholar
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity
D. Cecil, K. Park, E. Gad, J. Childs +3 more
2013Breast Cancer Research and Treatment19 citations
Semantic Scholar
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
J. Liao, R. Swensen, Kelsie J Ovenell, Katie M. Hitchcock-Bernhardt +8 more
2017Gynecologic Oncology15 citations Open access
Semantic Scholar
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
A. Coveler, V. Goodell, D. J. Webster, L. G. Salazar +4 more
2008Breast Cancer Research and Treatment15 citations
Semantic Scholar
Immunization with a plasmid DNA vaccine encoding the N-terminus of Insulin like Growth Factor Binding Protein-2 in advanced ovarian cancer leads to high level Type I immune responses
D. Cecil, J. Liao, Y. Dang, A. Coveler +5 more
2021Clinical Cancer Research14 citations Open access
Semantic Scholar
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer.
M. Disis, A. Coveler, D. Higgins, P. Fintak +6 more
201412 citations
Semantic Scholar
Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine
M. Disis, J. Strickler, D. Wallace, V. Goodell +6 more
20089 citations
Semantic Scholar
A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab.
D. J. Webster, J. Waisman, B. Macleod, C. Rosa +6 more
2006Journal of Clinical Oncology9 citations
Semantic Scholar
A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer
M. Disis, Y. Dang, A. Coveler, J. Childs +5 more
2023Clinical Cancer Research7 citations Open access
Semantic Scholar
Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.
J. Liao, W. Gwin, R. Urban, Katie M. Hitchcock-Bernhardt +12 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Abstract OT3-01-03: A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer
J. Childs, D. Higgins, K. DeShong, B. Heckman-Stoddard +5 more
20176 citations
Semantic Scholar
Abstract OT1-01-01: A phase I trial of the safety and immunogenicity of a multiple antigen vaccine (STEMVAC) in HER2 negative advanced stage breast cancer patients
D. Higgins, J. Childs, L. G. Salazar, M. Disis
20166 citations
Semantic Scholar
Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine.
M. Disis, L. G. Salazar, A. Coveler, J. Waisman +4 more
2009Journal of Clinical Oncology6 citations
Semantic Scholar
A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer.
L. G. Salazar, M. Slota, D. Wallace, D. Higgins +6 more
2009Journal of Clinical Oncology6 citations
Semantic Scholar
Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Vaccine Given Concurrently with Trastuzumab in Patients with Newly Diagnosed Advanced Stage Breast Cancer.
M. Disis, Y. Dang, N. Bates, D. Higgins +6 more
20096 citations
Semantic Scholar
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer
W. Gwin, L. G. Salazar, James Y. Dai, D. Higgins +8 more
2025Vaccines5 citations Open access
Semantic Scholar
Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.
M. Disis, Y. Dang, A. Coveler, D. Higgins +2 more
20213 citations
Semantic Scholar
Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2+ breast cancer.
M. Disis, A. Coveler, D. Higgins, Leonard D'Amico +7 more
20143 citations
Semantic Scholar
HER2/neu (HER2) specific T-cell immunity in patients with HER2+ inflammatory breast cancer (IBC) and prognosis.
L. G. Salazar, D. Wallace, P. Mukherjee, D. Higgins +4 more
2009Journal of Clinical Oncology3 citations
Semantic Scholar
Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.
W. Gwin, J. Childs, D. Higgins, Hania Shakalia +2 more
20182 citations
Semantic Scholar
Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity.
John Ben Liao, D. Cecil, Y. Dang, K. Baker +11 more
20162 citations
Semantic Scholar
Abstract P2-11-03: Phase I/II randomized study of combination immunotherapy with or without polysaccharide krestin (PSK) concurrently with a HER2 ICD peptide-based vaccine in patients with stage IV breast cancer receiving HER2-targeted monoclonal antibody therapy
L. G. Salazar, D. Higgins, J. Childs, A. Coveler +6 more
20162 citations
Semantic Scholar
Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.
John Ben Liao, R. Swensen, J. Reichow, Kelsie J Ovenell +6 more
20152 citations
Semantic Scholar
Abstract OT3-1-02: Phase II randomized study of combination immunotherapy with or without Polysaccharide Krestin (PSK®) concurrently with a HER2 ICD peptide-based vaccine and trastuzumab in patients with stage IV breast cancer
J. Childs, D. Higgins, S. Parker, J. Reichow +4 more
20122 citations
Semantic Scholar
P1-13-04: Phase II Study of Topical Imiquimod and Abraxane for Treatment of Breast Cancer Cutaneous Metastases.
L. G. Salazar, Hai-Ling Lu, H. Gray, D. Higgins +5 more
20112 citations
Semantic Scholar
A phase II study of the DNA plasmid-based vaccine STEMVAC in patients with metastatic triple-negative breast cancer (mTNBC).
Brie Chun, N. Hunter, W. Gwin, A. Coveler +11 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
OT1-02-10: Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients.
D. Higgins, J. Childs, S. Parker, K. Guthrie +2 more
20111 citations
Semantic Scholar
OT3-01-19: Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases.
D. Higgins, J. Childs, S. Parker, M. Disis +1 more
20111 citations
Semantic Scholar
A phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
Ron E. Swensen, J. Childs, D. Higgins, T. Gooley +4 more
2011Journal of Clinical Oncology1 citations
Semantic Scholar
549 Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer.
S. Stanton, J. Childs, D. Higgins, A. Kask +2 more
2022Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+ metastatic breast cancer.
W. Gwin, J. Childs, D. Higgins, K. Burton +5 more
20200 citations
Semantic Scholar
Patient specific characteristics associated with T-cell expansion for HER2/neu vaccine-primed autologous adoptive T-cell therapy.
L. Tachiki, Y. Dang, J. Childs, D. Higgins +4 more
20180 citations
Semantic Scholar
Abstract NTOC-097: VACCINATION TARGETING INSULIN–LIKE GROWTH FACTOR BINDING PROTEIN–2 (IGFBP–2) IN ADVANCED OVARIAN CANCER: SAFETY, IMMUNOGENICITY, AND SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) COMPARISON
J. Liao, D. Cecil, Y. Dang, K. Baker +11 more
20170 citations
Semantic Scholar
Abstract P2-11-05: Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients
R. Rengan, K. Baker, L. G. Salazar, J. Childs +4 more
20160 citations
Semantic Scholar
Abstract 3135: HER2 specific adoptive T cells shown to localize and infiltrate all sites of disease using combined SPECT and PET imaging
S. Stanton, J. Eary, Edmond A Marzbani, D. Mankoff +5 more
20150 citations
Semantic Scholar
Persistent immunity after therapeutic vaccination targeting HER2/neu correlated with post-vaccination magnitude of interferon gamma Elispot responses
J. Liao, J. Reichow, D. Higgins, J. Childs +2 more
2014Journal of Immunotherapy for Cancer0 citations Open access
Semantic Scholar
A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: Preliminary safety and immunogenicity
J. Liao, D. Cecil, J. Reichow, S. Parker +6 more
20140 citations
Semantic Scholar
Optimization of ex vivo expansion of HER2 specific polyfunctional Th1/Th17 cells from HER2 vaccine primed PBMC
Y. Dang, L. Salazar, J. Childs, D. Higgins +1 more
2013Journal of Immunotherapy for Cancer0 citations Open access
Semantic Scholar
Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
R. Swensen, B. Goff, J. Childs, D. Higgins +4 more
20120 citations
Semantic Scholar
Abstract P2-15-02: The efficacy of recruitment and retention strategies for research subjects in an early phase investigator-initiated breast cancer trial.
J. Reichow, D. Higgins, S. Parker, J. Childs +2 more
20120 citations
Semantic Scholar
Characterization of colon cancer-associated antigens that would be key therapeutic targets in the prevention of disease relapse or progression.
E. Broussard, A. Coveler, S. Whiting, R. Kim +7 more
2012Journal of Clinical Oncology0 citations
Semantic Scholar
OT2-05-05: Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming with a HER2 Peptide-Based Vaccine in Patients with Stage IV Breast Cancer.
S. Parker, D. Higgins, J. Childs, Y. Dang +4 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Childs×49
Invite
J. Childs — researcher profile on SciRah
M. Disis×47
Invite
M. Disis — researcher profile on SciRah
L. G. Salazar×33
Invite
L. G. Salazar — researcher profile on SciRah
A. Coveler×25
Invite
A. Coveler — researcher profile on SciRah

×22

Invite

Y. Dang — researcher profile on SciRah

Invite

J. Reichow — researcher profile on SciRah

Invite

J. Waisman — researcher profile on SciRah

Invite

M. Slota — researcher profile on SciRah

Invite

S. Parker — researcher profile on SciRah

Invite

B. Goff — researcher profile on SciRah

Invite

P. Fintak — researcher profile on SciRah

Invite

D. Cecil — researcher profile on SciRah